OncRef

Clinical Trial: NCT00792948

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:National Cancer Institute (NCI)
Information Provided By:National Cancer Institute (NCI)
Last Update Posted:2026-11-13

Study Overview

Brief Summary

This phase II trial is studying the side effects of giving combination chemotherapy together with or without donor stem cell transplant and to see how well it works in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect).

Official Title

Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)

Conditions

Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Adult L1 Acute Lymphoblastic Leukemia, Adult L2 Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia

Intervention / Treatment

  • Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
  • Drug: Cyclophosphamide
  • Drug: Cytarabine
  • Drug: Dasatinib
  • Drug: Dexamethasone
  • Drug: Doxorubicin Hydrochloride
  • Drug: Etoposide
  • Biological: Filgrastim
  • Other: Laboratory Biomarker Analysis
  • Drug: Leucovorin Calcium
  • Drug: Methotrexate
  • Drug: Methylprednisolone
  • Procedure: Peripheral Blood Stem Cell Transplantation
  • Drug: Prednisone
  • Drug: Sirolimus
  • Drug: Tacrolimus
  • Radiation: Total-Body Irradiation
  • Drug: Vincristine Sulfate

Other Study ID Numbers

  • NCI-2009-00800
  • NCI-2009-00800
  • S0805
  • CDR0000624250
  • S0805
  • S0805
  • U10CA180888
  • U10CA032102

Start Date (Actual)

2009-09-01

Primary Completion Date (Actual)

2016-06-01

Study Completion Date (Estimated)

2027-01-06

Enrollment (Actual)

97

Study Type

Interventional

Phase

Phase 2